Navigation Links
Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
Date:9/12/2007

September 11, 2007

WASHINGTON, Sept. 12 /PRNewswire-USNewswire/ -- The following is a statement by KCP Chairman Dr. Edward Jones:

Yesterday's FDA Advisory Committee meeting underscores the many considerations that must be factored in to policymaking related to anemia treatment in patients suffering from chronic kidney disease. The kidney community salutes FDA for working with scientists, practicing nephrologists, and other members of the medical community to achieve a consensus on hemoglobin and dosing levels for erythropoietin-stimulating agents (ESAs) based on different patient populations. The community is unified in its belief that patient quality of care and quality of life must be taken into account as physicians treat anemia in kidney patients. Patients with chronic kidney disease and those on dialysis depend on ESAs to stimulate red blood cell production in their bodies.

Anemia-management drugs have been well demonstrated to improve quality of life for kidney patients and provide significant medical benefits. Unlike patients with cancer, patients with chronic kidney disease are permanently affected by anemia, which in turn affects their ability to engage in day-to- day activities that non-patients take for granted -- caring for their families, holding a job, and going to school. Without ESA therapy, ESRD patients may develop hemoglobin levels that are dangerously low. Before ESAs were available, blood transfusions were required in most kidney patients. Transfused patients often suffered from heart failure, iron overload, and other chronic problems.

Several studies have demonstrated improvement in the morbidity and mortality of patients with kidney disease and kidney failure by the appropriate management of their anemia. After extensive review of the results of six new studies, a National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) work group updated its Clinical Practice Guidel
'/>"/>

SOURCE Kidney Care Partners
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Obama Statement on Bush Veto of Stem Cell Bill
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
7. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
8. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
11. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015  Oxis Biotech, Inc. ... International, Inc. [OTC: OXIS] and [Euronext Paris: ... exclusive option agreement with the University of ... by Dr. Xiang-Qun Xie , Associate ... Sciences, School of Pharmacy.  These patents/intellectual properties ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
(Date:3/26/2015)... , March 26, 2015  CNBC profiled MJ Freeway ... part of a series "How I Did It," which features ... the High Road" released yesterday, illustrates how two tech ... leading IT providers to the marijuana industry. ... describes how Co-Founders Amy Poinsett and Jessica Billingsley ...
Breaking Medicine Technology:Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2MJ Freeway, Industry-Leading Software Solution for Cannabis Businesses, Featured in CNBC Special "How I Did It" 2
(Date:3/26/2015)... York (PRWEB) March 26, 2015 ... move forward nationwide, with the issuance of new ... Pennsylvania and Louisiana. According to an Order dated ... litigation established for Xarelto injury claims in the ... now allow plaintiffs to file cases directly in ...
(Date:3/26/2015)... March 26, 2015 “The SWEET Act is ... healthy options more available and help parents who are working ... is a reasonable approach to support public health, and we ... issue for the health of all families,” said Dr. Jane ... Health on the introduction of the Sugar-Sweetened Beverage Tax (SWEET) ...
(Date:3/26/2015)... CA (PRWEB) March 26, 2015 Dr. ... are proud to announce expanded offerings for Bay Area ... Francisco Dental Implant Center has long been a top-rated ... expanded its offerings to meet the strong demand by ... our reputation as a top-rated dental implant facility in ...
(Date:3/26/2015)... Altamonte Springs, FL (PRWEB) March 26, 2015 ... one of the nation’s leading innovative specialty pharmacies, ... newly created position of Vice President of Pharmaceutical ... for fostering beneficial connections with our pharmaceuticals partners ... pharmaceutical relationships in support of BioPlus’ expansion. ...
(Date:3/26/2015)... London, UK (PRWEB) March 26, 2015 In ... 40 billion as of 2013 and is set to decrease ... billion by 2020; the growth is expected up to 2017 ... growth is expected to be owing to the surging penetration ... Tekturna HCT, Twynsta, Micardis Plus, Valturna, Benicar HCT, and Tekamlo), ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 2Health News:Xarelto Lawsuits Move Forward Nationwide, With Issuance of New Court Docs in State, Federal Litigations 3Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 2Health News:Bay Area Dental Implant Specialist, Dr. Alex Rabinovich Announces Regional Educational Strategy 3Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 2Health News:Top 8 Developed Anti-Hypertensive Therapeutics Markets Discussed in New GBI Research Report Published at MarketPublishers.com 3
... 81-year-old San Francisco woman with dementia, little money and an equally aged ... A 72-year-old Riverside woman with Alzheimer,s who cannot be left safely on ... care for her. A 78-year-old Los Angeles ... take care of him if day care services are cut. ...
... Angeles, London, New Delhi, Singapore and Washington DC (October ... with diabetes to modify their behavior, adjust their medicine ... to a recent study, published by SAGE in ... testing," a self-monitored testing both before and after specific ...
... remains a mystery, , THURSDAY, Oct. 1 (HealthDay News) -- ... still in their mother,s womb were about 20 percent more ... study has found. , The flu outbreak in 1918 killed ... the United States. That flu, like the current H1N1 swine ...
... ... to maximize cell culture media performance and will be on display at BioProcess International ... in Raleigh, North Carolina. , ... Fort Collins, CO (PRWEB) October 1, 2009 -- As conference exhibitor and ...
... The 2nd ... in New York, NY. This three-day conference will explore address all aspects of signal detection ... ... The 2nd DIA Conference on Signal Detection and Data Mining will be held ...
... Support for Addressing Crisis of Chronic Disease , ... are voicing their support for health reform that prioritizes ... to Health Reform" ( www.sayyestohealthreform.com ) - an ... (PFCD) directed at Congressional leaders in Washington. , The campaign ...
Cached Medicine News:Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 2Health News:Half-million low-income elderly affected by sweeping cuts to state safety net 3Health News:Pre-Birth Exposure to 1918 Flu Raised Heart Risks, Study Finds 2Health News:Pre-Birth Exposure to 1918 Flu Raised Heart Risks, Study Finds 3Health News:InVitria's Better Ingredients for Better Media to be Showcased at BPI '09 2Health News:International Experts to Review State-of-the-Art Thinking on Signal Detection and Data Mining 2Health News:International Experts to Review State-of-the-Art Thinking on Signal Detection and Data Mining 3Health News:Maryland Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 2Health News:Maryland Residents Participate in Launch of National Video Campaign: 'Say 'Yes' to Health Reform' 3
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Sodium in serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: